Eric Jou

Dr. Eric Jou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JHJamie Sin Ying Ho
Jamie Sin Ying Ho
EJEric Jou
Eric Jou
PKPek Lan Khong
Pek Lan Khong
RFRoger S. Y. Foo
Roger S. Y. Foo
Ching-Hui SiaChing-Hui Sia
Ching-Hui Sia
Heart failure is a clinical syndrome with rising global incidence and poor prognosis despite improvements in medical therapy. There is increasing research interest in epigenetic therapies for heart failure. Pathological cardiac remodelling may be driven by stress-activated cardiac signalling cascades, and emerging research has shown the involvement of epigenetic signals that regulate transcriptional changes leading to heart failure. In this review, we appraise the current evidence for the role of epigenetic modifications in heart failure. These include DNA methylation and histone modifications by methylation, acetylation, phosphorylation, ubiquitination and sumoylation, which are critical processes that establish an epigenetic pattern and translate environmental stress into genetic expression, leading to cardiac remodeling. We summarize the potential epigenetic therapies currently in development, including the limited clinical trials of epigenetic therapies in heart failure. The dynamic changes in the epigenome in the disease process require further elucidation, and so does the impact of this process on the development of therapeutics. Understanding the role of epigenetics in heart failure may pave the way for the identification of novel biomarkers and molecular targets, and facilitate the development of personalized therapies for this important condition.

26 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
CKCharlene H. P. Kok
Charlene H. P. Kok
MNMegan Bi-Jia Ng
Megan Bi-Jia Ng
SLShaun Loong
Shaun Loong
EJEric Jou
Eric Jou
PLPoh San Lai
Poh San Lai
Advances in stroke genetics have highlighted the critical role of rare genetic variants in cerebrovascular diseases, with RNF213 emerging as a key player in ischemic stroke and Moyamoya disease (MMD). Initially identified as the primary susceptibility gene for MMD, RNF213—notably the p.R4810K variant—has been strongly linked to intracranial artery stenosis (ICAS) and various ischemic stroke subtypes, particularly in East Asian populations. This gene encodes an E3 ubiquitin ligase with diverse roles in angiogenesis, vascular remodeling, lipid metabolism, and cerebral blood flow regulation, yet its exact mechanisms in cerebrovascular pathology remain incompletely understood. This review synthesizes findings from genetic studies, as well as cellular and animal models, to provide a holistic understanding of RNF213’s involvement in cerebrovascular diseases. Key mechanisms by which RNF213 variants contribute to disease pathogenesis are explored, alongside discussions on their clinical utility as biomarkers and therapeutic targets. Additionally, we address the gene’s implications for disease prediction, risk assessment, and cascade screening. By integrating evidence across disciplines, this review identifies critical knowledge gaps, including the biological pathways underlying RNF213’s pathogenicity. These insights lay the groundwork for future research and underscore the potential of RNF213 in driving personalized approaches to cerebrovascular disease management.

11 November 2025 in MUSCULOSKELETAL SURGERY
Verified
Journal Article
Closed access
PDF file
RPReece Patel
Reece Patel
KSKhalil Saadeh
Khalil Saadeh
OBOwain Bates
Owain Bates
ABAniqah Bhatti
Aniqah Bhatti
EJEric Jou
Eric Jou
VSVeenesh Selvaratnam
Veenesh Selvaratnam